Orlistat

SIGMA/O4139 - ≥98%, solid

Synonym: (−)-Tetrahydrolipstatin; N-Formyl-L-leucine (1S)-1-[[(2S,3S)-3-hexyl-4-oxo-2-oxetanyl]methyl]dodecyl ester; Ro-18-0647

CAS Number: 96829-58-2
Empirical Formula (Hill Notation): C₂₉H₅₃NO₅
Molecular Weight: 495.73
MDL Number: MFCD05662360
Linear Formula: C₂₉H₅₃NO₅
Product Type: Chemical

Catalog Number	PKG Qty.	Price


45-O4139-25MG	25 mg	$179.00 1/EA	Add To Favorites
45-O4139-100MG	100 mg	$598.00 1/EA	Add To Favorites

This picture is provided solely for illustration purposes. Optical properties of the actual product may deviate. Relevant product information is printed on labeled products and other accompanying or available information material. This image depicts SKU: O4139-100MG

Properties
Descriptions
Safety Info.
Basic Data

assay	≥98%
biological source	synthetic (organic)
color	white
form	solid
InChI	1S/C29H53NO5/c1-5-7-9-11-12-13-14-15-16-18-24(34-29(33)26(30-22-31)20-23(3)4)21-27-25(28(32)35-27)19-17-10-8-6-2/h22-27H,5-21H2,1-4H3,(H,30,31)/t24-,25-,26-,27-/m0/s1
InChI key	AHLBNYSZXLDEJQ-FWEHEUNISA-N
mp	<50 °C
originator	Roche
Quality Level	200
SMILES string	CCCCCCCCCCC[C@@H](C[C@@H]1OC(=O)[C@H]1CCCCCC)OC(=O)[C@H](CC(C)C)NC=O
solubility	DMSO: 19 mg/mL
storage temp.	2-8°C

Application:	Orlistat has been used as an inhibitor: • of fatty acid synthase in long-term estrogen-deprived (LTED) variant cell lines • of lipase in screening lipase inhibition by raspberry extract • in in vitro pancreatic lipase activity assay
Biochem/physiol Actions:	Orlistat impairs intestinal fat absorption and is effective in weight management. It is regarded as a safe drug for treating obesity. It delays the progression of type 2 diabetes mellitus especially in obese and improves glycemic parameters. Long term usage of orlistat results in improved weight reduction and it may not contribute in colorectal carcinogenesis.
Biochem/physiol Actions:	Orlistat, used in obesity research, is a pancreatic lipase inhibitor that acts locally in the gastrointestinal tract to inhibit lipase.
Features and Benefits:	This compound was developed by Roche . To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here .
General description:	Orlistat acts as a gastric lipase inhibitor that reduces fat absorption.
Other Notes:	Solution is not completely clear, small particles may remain floating.
Packaging:	25, 100 mg in glass bottle

RIDADR	NONH for all modes of transport
WGK Germany	WGK 3
Flash Point(F)	Not applicable
Flash Point(C)	Not applicable

Purity	≥98%
mp	<50 °C
Storage Temp.	2-8°C
UNSPSC	41106300

To Order From a Quote